NCT00984802View on ClinicalTrials.gov

Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

April 30, 2011

Conditions
Stable Coronary Artery DiseasePercutaneous Coronary Intervention
Interventions
DRUG

CMX-2043

Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.

DRUG

Placebo control

Vehicle solution for IV administration single dose.

Trial Locations (5)

27705

Duke University Hospital, Durham

01608

St. Vincent Hospital, Worcester

600 037

Madras Medical Mission, Chennai

400 016

Hinduja Hospital, Mumbai

411 030

Poona Hospital, Pune

Sponsors

Lead Sponsor

Ischemix, LLC
All Listed Sponsors
lead

Ischemix, LLC

INDUSTRY